Comparing the effects of cabergoline and hydroxychloroquine to prevent ovarian hyperstimulation syndrome

Comparing the effects of cabergoline and hydroxychloroquine to prevent ovarian hyperstimulation syndrome (OHSS) in PCOS patients undergoing infertility treatment.

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20240305061171N1

Enrollment

Registered

2024-06-29

Start date

2024-04-03

Completion date

Unknown

Last updated

2024-07-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Polycystic ovary syndrome. Polycystic ovarian syndrome

Interventions

Intervention 1: Intervention group 1: administration of cabergoline. This group is under ART with antagonist cycle. At the beginning of the cycle, gonadotropin is used with a dose of 150 units, and in

Eligibility

Sex/Gender

Female

Age

18 Years to 40 Years

Inclusion criteria

Inclusion criteria: Polycystic ovary syndrome according to Rotterdam criteria Age 18 to 40 years The number of antral follicles (AFC) above 20 Anti-Müllerian hormone (AMH) more than 3.36 ng/ml Body mass index (BMI) less than 30 kg/m2

Exclusion criteria

Exclusion criteria: Suffering from endometriosis Decreased ovarian reserve Chromosomal abnormalities History of sensitivity to drugs that inhibit dopamine or cabergoline Patients who do not take the desired drugs on a daily basis

Design outcomes

Primary

Measure	Time frame
Primary outcome: Ovarian hyperstimulation syndrome (OHSS). Timepoint: After the intervention. Method of measurement: Based on clinical criteria, ultrasound and tests performed.	—

Secondary

Measure	Time frame
Secondary outcome: Blood creatinine level. Timepoint: Before starting the intervention, After the intervention. Method of measurement: Based on laboratory results.;Secondary outcome: Blood sodium level. Timepoint: Before starting the intervention, After the intervention. Method of measurement: Based on laboratory results.;Secondary outcome: Blood potassium level. Timepoint: Before starting the intervention, After the intervention. Method of measurement: Based on laboratory results.;Secondary outcome: Blood Hematocrit. Timepoint: Before starting the intervention, After the intervention. Method of measurement: Based on laboratory results.;Secondary outcome: Blood urea level. Timepoint: Before starting the intervention, After the intervention. Method of measurement: Based on laboratory results.	—

Measure

Time frame

Secondary outcome: Blood creatinine level. Timepoint: Before starting the intervention, After the intervention. Method of measurement: Based on laboratory results.;Secondary outcome: Blood sodium level. Timepoint: Before starting the intervention, After the intervention. Method of measurement: Based on laboratory results.;Secondary outcome: Blood potassium level. Timepoint: Before starting the intervention, After the intervention. Method of measurement: Based on laboratory results.;Secondary outcome: Blood Hematocrit. Timepoint: Before starting the intervention, After the intervention. Method of measurement: Based on laboratory results.;Secondary outcome: Blood urea level. Timepoint: Before starting the intervention, After the intervention. Method of measurement: Based on laboratory results.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactElnaz Salari

Tehran University of Medical Sciences

dr.elnazz.salari@gmail.com+98 21 7788 3283

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 5, 2026